| Code | CSB-RA015007MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Ocaratuzumab, targeting MS4A1 (Membrane Spanning 4-Domains A1), also known as CD20. MS4A1 is a B-cell specific surface antigen expressed during B lymphocyte development from the pre-B cell stage through mature B cells, but absent on plasma cells. This transmembrane phosphoprotein regulates B-cell activation and plays a crucial role in calcium influx across cell membranes. MS4A1 is critically implicated in B-cell malignancies including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and various autoimmune disorders where aberrant B-cell activity drives pathogenesis.
Ocaratuzumab is a humanized type I anti-CD20 monoclonal antibody engineered with glycoengineering modifications to enhance antibody-dependent cellular cytotoxicity compared to earlier CD20-targeting therapeutics. This biosimilar antibody serves as a valuable research tool for investigating B-cell biology, exploring mechanisms of B-cell depletion, studying lymphoproliferative disorders, and evaluating immune-mediated diseases. It supports investigations into antibody-mediated effector functions and complement-dependent cytotoxicity pathways relevant to therapeutic development.
There are currently no reviews for this product.